Role of Noninsulin Therapies in the Treatment of Type 1 Diabetes
Sara E. Lingow,1,2 Sandra D. Burke,3 Amie D. Brooks,1 and Pat S. Rafferty1

1St. Louis College of Pharmacy, St. Louis, MO
2St. Louis County Department of Public Health, St. Louis, MO
3Goldfarb School of Nursing at Barnes-Jewish College, St. Louis, MO

S.E.L. is currently affiliated with Banner Health, Loveland, CO.

https://doi.org/10.2337/ds18-0058

©2018 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See http://creativecommons.org/licenses/by-nc-nd/3.0 for details.
use (3). The role of two other non-insulin classes of medications, sodium–glucose cotransporter (SGLT) inhibitors and glucagon-like peptide 1 (GLP-1) receptor agonists, have also been studied in type 1 diabetes. This literature review focuses on the use of these agents in patients with type 1 diabetes and provides a critical appraisal of evidence regarding their efficacy and safety for this purpose.

**SGLT Inhibitors**

Located in the proximal tubule of the nephron, the SGLT2 receptor is responsible for 90% of renal glucose reabsorption. Inhibition of this transporter reduces reabsorption of filtered glucose, thereby increasing glucosuria and reducing plasma glucose concentrations (7). The SGLT1 receptor is located in both the proximal renal tubule and the proximal small intestine. In the proximal renal tubule, it is responsible for reabsorption of the remaining 10% of renal glucose. In the small intestine, it is the primary transporter in glucose and galactose absorption (11,12). Because the mechanism of SGLT inhibitors is independent of β-cell function, this drug class may offer glucose-lowering benefit to patients with type 1 diabetes (3). Known adverse effects of SGLT inhibitors include lipid abnormalities, genital infections, hypotension, and euglycemic DKA (7). A list of available SGLT inhibitors can be found in Table 1.

Early studies of SGLT inhibitors in patients with type 1 diabetes demonstrated modest improvements in glycemic control, weight reduction, and insulin dose reduction but were limited by small sample sizes and short durations. Although these benefits were promising, patients receiving SGLT inhibitors also experienced more episodes of ketoacidosis and genital mycotic infections (11,13–16). Two large-scale clinical trials evaluating the role of SGLT inhibitors in type 1 diabetes are described in Table 2. The DEPICT-1 trial (17) evaluated the safety and efficacy of dapagliflozin, an SGLT2 inhibitor, added to insulin therapy in 833 patients with type 1 diabetes over 24 weeks. The primary outcome, change in A1C at 24 weeks, statistically favored treatment with dapagliflozin 5 or 10 mg compared to placebo. Severe hypoglycemia occurred in 21 (8%), 19 (6%), and 19 (7%) of the patients in the dapagliflozin 5 mg, dapagliflozin 10 mg, and placebo groups, respectively. Adjudicated definite DKA occurred in four (1%), five (2%), and three (1%) patients in the dapagliflozin 5 mg, dapagliflozin 10 mg, and placebo groups, respectively. This trial excluded patients with a recent history of severe hypoglycemia or DKA.

The inTandem 3 trial (12) evaluated the safety and efficacy of sotagliflozin, an SGLT1 and SGLT2 inhibitor, in 1,402 patients with type 1 diabetes over 24 weeks. The combined safety and efficacy primary outcome was the proportion of patients achieving an A1C <7.0% without hypoglycemia or DKA. Two hundred of the patients in the sotagliflozin group (28.6%) achieved this primary outcome, whereas 107 (15.2%) patients in the placebo group achieved the outcome, resulting in a number needed to treat of eight. Conversely, of patients who failed to meet the target A1C, more patients in the sotagliflozin group had at least one episode of DKA compared to placebo (16 [2.3%] vs. 13 [1.8%], respectively, P <0.003), resulting in a number needed to harm of 50. The rate of DKA events in the sotagliflozin group was higher in patients who used an insulin pump compared to those who did not use an insulin pump. As in the DEPICT-1 study, this trial excluded patients with a recent history of DKA or hypoglycemia.

The data from these two landmark trials further support the benefits of reduction in A1C, weight, and insulin TDD with SGLT inhibitors. Although both trials excluded patients with a recent history of severe hypoglycemia, there is no indication in the literature of an increased risk of hypoglycemia with these agents. There is a risk of ketoacidosis; therefore, these agents should not be used in patients with a history of or who are known to be at increased risk for DKA.

A position statement from the American Association of Clinical Endocrinologists and American College of Endocrinology recommends that future trials of SGLT inhibitors in type 1 diabetes should use lower doses of these agents and that insulin doses should not be routinely reduced on initiation of an SGLT inhibitor (18). Future trials that are longer in duration and specifically designed to evaluate the long-term safety of these medications in patients with type 1 diabetes are essential. Additionally, future studies should evaluate the benefit of this class in the prevention or delay of microvascular and macrovascular complications of diabetes.

**GLP-1 Receptor Agonists**

Human GLP-1 is a peptide that, in conjunction with glucose-dependent insulinoic polypeptide, is responsible for >90% of the increased insulin secretion after an oral glucose load. Human GLP-1 levels rise shortly after food ingestion, enhancing insulin secretion, suppressing glucagon secretion, slowing gastric emptying, and reducing food intake by increasing satiety (19). GLP-1 receptor agonists are analogs of human GLP-1 that increase glucose-dependent insulin secretion, delay inappropriate glucagon secretion, delay gastric emptying, and decrease food intake. Animal models and in vitro data have also demonstrated increased β-cell growth and replication. The proposed benefit of GLP-1 receptor agonists in type 1 diabetes is mostly related to the mechanistic avenues independent of β-cell function. However, the potential to improve residual β-cell function and increase glucose-dependent insulin secretion may be beneficial early in the diagnosis of type 1 diabetes.

The most common adverse effects of GLP-1 receptor agonists include...
| Available SGLT Inhibitors and GLP-1 Receptor Agonists (7,11–17,21–29,36,37) | Available Doses | Administration | Average Wholesale Price for 30 Days* | Studies in Type 1 Diabetes |
|---|---|---|---|---|
| **SGLT inhibitors** | | | | |
| Canagliflozin | 100 and 300 mg | By mouth once daily | $557.50 | Henry et al., 2015 (15) |
| Dapagliflozin | 5 and 10 mg | By mouth once daily | $557.45 | Kuhadiya et al., 2016 (16) |
| Empagliflozin | 10 and 25 mg | By mouth once daily | $557.94 | Perkins et al., 2014 (13) |
| Sotagliflozin† | 400 mg | By mouth once daily | — | Sands et al., 2015 (11) |
| **GLP-1 receptor agonists** | | | | |
| Albiglutide | 30 and 50 μg | SQ injection once weekly | $626.41 | Not studied |
| Dulaglutide | 0.75 and 1.5 mg | SQ injection once weekly | $876.24 | Not studied |
| Exenatide | 5 and 10 μg | SQ injection twice daily | $850.06 | Hari Kumar et al., 2013 (23) |
| Exenatide ER | 2 mg | SQ injection once weekly | $792.19 | Traina et al., 2014 (24) |
| Liraglutide | 0.6, 1.2, 1.8, and 3.0 mg‡ | SQ injection once daily | 0.6 and 1.2 mg: $645.34 1.8 mg: $968.00 3.0 mg: $1,440.50‡ | Kielgast et al., 2011 (21) Kuhadiya et al., 2013, 2016 (22,27) Frandsen et al., 2015 (25) Dejgaard et al., 2016 (26) Mathieu et al., 2016 (28) Ahrén et al., 2016 (29) Dubé et al., 2018 (36) |
| Lixisenatide | 10 and 20 μg | SQ injection once daily | $707.42 | Not studied |
| Semaglutide | 0.25, 0.5, and 1 mg | SQ injection once weekly | $811.20 | Not studied |

*Average wholesale price per package as of 18 June 2018. †Dual SGLT1 and SGLT2 inhibitor; not approved for use in the United States. ‡3.0 mg dose is approved by the FDA for the treatment of obesity only. SQ, subcutaneous.
nausea and vomiting, increased heart rate, and headache. This class should not be used in patients with a personal or family history of thyroid cancer or multiple endocrine neoplasia syndrome (7,20). A list of GLP-1 receptor agents can be found in Table 1.

Preliminary literature evaluating the role of GLP-1 receptor agonists in type 1 diabetes is largely inconclusive. Except for one 56-week trial, most trials had small sample sizes and short durations ranging from 4 to 26 weeks. The results of the trials were variable with regard to A1C reduction (–0.3 to –2.3%), weight loss (–0.5 to –6 kg), and reduction in TDD of insulin up to 20%. Although the benefits demonstrated in these early studies are promising, many of the studies were retrospective, open-label, or observational, limiting their usefulness (21–27).

Two large-scale trials examining the use of GLP-1 receptor agonists in type 1 diabetes are described in Table 3. The ADJUNCT-ONE (28) trial evaluated the safety and efficacy of liraglutide added to treat-to-target insulin with regard to effects on A1C, insulin requirement, and body weight in adults with type 1 diabetes over 52 weeks. A statistically significant decrease in A1C and insulin TDD was seen with liraglutide 1.2 and 1.8 mg doses compared to placebo. All three doses of liraglutide were associated with weight loss. Although benefits were seen at the higher doses of liraglutide, they were accompanied by an increased rate of hypoglycemic events. The rate of symptomatic hypoglycemic events observed was 16.5/patient-year of exposure (PYE) and 16.1 PYE in the liraglutide 1.8 and 1.2 mg groups, respectively, compared to placebo (12.3/PYE). There were a total of eight adjudicated events of DKA in all three liraglutide groups combined. In all but one of these events, a clinically relevant TABLE 2. Landmark Trials of SGLT Inhibitors in Type 1 Diabetes

| Trial                  | Comparison                        | Baseline A1C, % | Baseline C-Peptide–Positive, % | Change in A1C Versus Placebo, % | Change in TDD Versus Placebo, % | Change in Weight Versus Placebo, kg |
|------------------------|-----------------------------------|----------------|-------------------------------|-------------------------------|-------------------------------|-------------------------------------|
| Dandona et al., 2017   | Dapaglifozin 5 and 10 mg + TTT insulin vs. placebo (n = 833) | D5: 8.52       | L0.6: 21.6                    | D5: –0.42*                    | D5: –8.8*                     | D5: –2.96*                          |
| “DEPICT-1” (17)        | D10: 8.50                         | D10: 16.2      | L1.2: –0.15*                  | D10: –13.2*                   | D10: –3.72*                    |
| Garg et al., 2017      | Sotaglifozin 400 mg + TTT insulin vs. placebo (n = 1,402)     | SOT: 8.26      | L1.8: –0.20*                  | –0.46*                        | –9.9*                          | –2.98*                              |

*Statistically significant difference. D5, dapaglifozin 5 mg; D10, dapaglifozin 10 mg; P, placebo; SOT, sotaglifozin; TTT, treat-to-target.

TABLE 3. Landmark Trials of GLP-1 Receptor Agonists in Type 1 Diabetes

| Trial                  | Comparison                        | Baseline A1C, % | Baseline C-Peptide–Positive, % | Change in A1C Versus Placebo, % | Change in TDD Versus Placebo, % | Change in Weight Versus Placebo, kg |
|------------------------|-----------------------------------|----------------|-------------------------------|-------------------------------|-------------------------------|-------------------------------------|
| Mathieu et al., 2016   | Liraglutide 0.6, 1.2, and 1.8 mg + TTT insulin versus placebo | L0.6: 8.18      | L0.6: 21.6                    | L0.6: –0.09                    | L0.6: 0                        | L0.6: –2.2*                          |
| “ADJUNCT-ONE” (28)     | L0.6: 8.18                        | L1.2: 8.16      | L1.2: 16.2                    | L1.2: –0.15*                   | L1.2: –2*                      | L1.2: –3.6*                          |
|                        | L1.8: 8.14                        | L1.8: 16.9      | L1.8: –0.20*                  | L1.8: –5*                      | L1.8: –9.9*                    | L1.8: –4.9*                          |
|                        | P: 8.15                           | P: 14.9         |                               |                               |                               |                                     |
| Ahren et al., 2016     | Liraglutide 0.6, 1.2, and 1.8 mg + capped insulin versus placebo | L0.6: 8.09      | L0.6: 24*                     | L0.6: –0.24*                   | L0.6: –5*                      | L0.6: –2.5*                          |
| “ADJUNCT-TWO” (29)     | L0.6: 8.09                        | L1.2: 8.07      | L1.2: 16                      | L1.2: –0.23*                   | L1.2: –7*                      | L1.2: –4.0*                          |
|                        | L1.8: 8.04                        | L1.8: 16        | L1.8: –0.35*                  | L1.8: –10*                     | L1.8: –5.1*                    | L1.8: –5.1*                          |
|                        | P: 8.12                           | P: 11           |                               |                               |                               |                                     |

*Statistically significant difference. L0.6, liraglutide 0.6 mg; L1.2, liraglutide 1.2 mg; L1.8, liraglutide 1.8 mg; P, placebo.
Lastly, gastrointestinal adverse effects, particularly nausea, were notable in all liraglutide groups. The ADJUNCT-ONE authors identified that patients with residual C-peptide levels at baseline had a greater decrease in A1C with liraglutide 1.8 and 1.2 mg compared to those without residual C-peptide at the same doses. Additionally, patients with residual C-peptide experienced fewer episodes of hypoglycemia or hyperglycemia with ketosis.

The ADJUNCT-TWO trial (29) evaluated the efficacy and safety of liraglutide added to a capped insulin dose in patients with type 1 diabetes over 26 weeks. All three doses of liraglutide demonstrated a statistically significant decrease in A1C, insulin TDD, and body weight compared to placebo. The highest rate of symptomatic hypoglycemia was unexpectedly seen in the liraglutide 1.2 mg arm. As in the ADJUNCT-ONE trial, hyperglycemia with ketosis was seen most often in the liraglutide 1.8 mg arm. The subgroup analysis of ADJUNCT-TWO revealed that patients with residual C-peptide at baseline showed a greater reduction in A1C with liraglutide 1.8 mg compared to those without residual C-peptide (29).

ADJUNCT-ONE and ADJUNCT-TWO are the largest trials available to date evaluating liraglutide in type 1 diabetes. Although the results of both trials are promising with regard to A1C reduction, weight loss, and reduction in insulin requirements, the treatment did show an increased risk of dose-dependent hypoglycemia and hyperglycemia with ketosis, as well as gastrointestinal adverse events. Future studies focused on prevention of microvascular or macrovascular outcomes would be beneficial to truly determine the clinical utility of this class in type 1 diabetes.

Comparing SGLT Inhibitors and GLP-1 Receptor Agonists in Type 1 Diabetes

Overall, the benefits of both SGLT inhibitors and GLP-1 receptor agonists in addition to insulin therapy in type 1 diabetes appear to be promising. However, the potential for adverse effects, lack of FDA approval for use in type 1 diabetes, the additional cost of the therapeutic regimen (Table 1), as well as a lack of insurance coverage for drugs in either class for patients with type 1 diabetes limit the practicality of their use at present.

Given these constraints, patients with type 1 diabetes who are overweight or obese and interested in an oral agent may be good candidates for an SGLT inhibitor. Duration of diabetes does not appear to be a factor affecting the efficacy of SGLT inhibitors in type 1 diabetes. Because the trials did not show an increased rate of hypoglycemia in patients with type 1 diabetes, agents from this class might be an option if used with caution in patients who are at risk for hypoglycemia. However, this class should be avoided in patients with a recent history of or who are known to be at increased risk of a DKA episode. Patients on insulin pumps may be at higher risk of DKA due to mechanical pump failures; therefore, extreme caution should be used if recommending an SGLT inhibitor for patients using an insulin pump. Sotagliflozin is the only SGLT inhibitor currently under FDA review for potential approval of use in type 1 diabetes. The FDA is expected to take action on this in March 2019 (30).

A GLP-1 receptor agonist may be a better option in patients with newer-onset type 1 diabetes, residual β-cell function, or residual C-peptide levels, given that the preliminary literature and subgroup analyses show the most benefit in this population. Obese and overweight patients with type 1 diabetes may benefit from the weight loss properties of GLP-1 receptor agonists, but drugs from this class should be used with caution in patients at a higher risk of DKA or hypoglycemic events, as the recent evidence showed a higher incidence of these adverse effects. Similar to pramlintide, GLP-1 receptor agonists would add an undesirable additional injection to the medication regimen in this patient population. However, a GLP-1 receptor agonist is a once-daily or once-weekly injection, whereas pramlintide must be injected before each meal three to four times per day.

Paradigm Shift

Landmark trials such as the Diabetes Control and Complications Trial and its long-term follow-up the Epidemiology of Diabetes Interventions and Complications study have demonstrated that there is a direct, inverse correlation between duration of time within glycemic targets and risk of microvascular and macrovascular complications (31,32). In recent years, the overall approach to medication management in type 2 diabetes has changed from a primary focus on A1C lowering to a broader focus on the reduction of complication risk via nonglycemic pathways. This shift is, in large part, due to results of trials such as LEADER (Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results), CANVAS (Canagliflozin Cardiovascular Assessment Study), and EMPA-REG OUTCOME (BI 10773 [Empagliflozin] Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients), which have shown cardiovascular and renal benefits irrespective of A1C lowering with the use of specific drug classes in patients with type 2 diabetes and elevated cardiovascular risk (33–35). Perhaps there is also more to prevention of complications in patients with type 1 diabetes than merely striving for glycemic goals with the use of insulin. These non-insulin agents may have pleiotropic benefits that extend beyond glycemic control. Future trials evaluating the prevention of microvascular and
macrovascular complications with SGLT inhibitors and GLP-1 receptor agonists in the treatment of type 1 diabetes have the potential to transform current treatment algorithms.

Duality of Interest
S.D.B. serves as an associate editor of Diabetes Spectrum but was not involved in reviewing or accepting this article. No other potential conflicts of interest relevant to this article were reported.

Author Contributions
S.E.L. researched literature, wrote the manuscript, contributed to discussion, and reviewed and edited content. S.D.B. contributed to discussion and reviewed and edited the manuscript. A.D.B. researched data, contributed to discussion, and reviewed and edited the manuscript. P.S.R. researched literature, contributed to discussion, and reviewed and edited the content. S.E.L. is the guarantor of this work and, as such, had full access to all the literature reviewed and takes responsibility for the integrity of the literature evaluation and the accuracy of this manuscript.

References
1. Bullard KM, Cowie CC, Lessem SE, et al. Prevalence of diagnosed diabetes in adults by diabetes type—United States, 2016. MMWR Mortal Wkly Rep 2018;67:359–361
2. American Diabetes Association. Classification and diagnosis of diabetes. Standards of Medical Care in Diabetes—2018. Diabetes Care 2018;41(Suppl. 1):S13–S27
3. Franden CS, DeJgaard TF, Madsbad S. Non-insulin drugs to treat hyperglycaemia in type 1 diabetes mellitus. Lancet Diabetes Endocrinol 2016;4:766–780
4. Miller KM, Foster NC, Beck RW. Current state of type 1 diabetes treatment in the U.S.: updated data from the TID exchange clinic registry. Diabetes Care 2015;38:971–978
5. Schwartz SS, Epstein S, Corkey BE, et al. The time is right for a new classification system for diabetes: rationale and implications of the beta-cell-centric classification schema. Diabetes Care 2016;39:179–186
6. Symlin (pramlintide) [package insert]. Wilmington, Del., AstraZeneca Pharmaceuticals, June 2014
7. Lexicomp Online. Lexi-Drugs. Hudson, Ohio. Lexi-Comp, updated September 2017. Available from online.lexicomp.com. Accessed October 2017
8. Whitehouse F, Kruger DF, Fineman M, et al. A randomized study and open-label extension evaluating the long-term efficacy of pramlintide as adjunct to insulin therapy in type 1 diabetes. Diabetes Care 2002;25:724–730
9. Ratner RE, Dickey R, Fineman M, et al. Amylin replacement with pramlintide as adjunct to insulin therapy improves long-term glycaemic and weight control in type 1 diabetes mellitus: a 1-year randomized controlled trial. Diabet Med 2004;21:1204–1212
10. Edelman S, Garg S, Frias J, et al. A double-blind, placebo-controlled, trial assessing pramlintide treatment in the setting if intensive insulin therapy in type 1 diabetes. Diabetes Care 2006;29:2189–2195
11. Sands AT, Zambrowicz BP, Rosenstock J, et al. Sotagliflozin, a dual SGLT1 and SGLT2 inhibitor, as adjunct therapy to insulin in type 1 diabetes. Diabetes Care 2015;38:1181–1188
12. Garg SK, Henry RR, Banks P, et al. Effects of sotagliflozin added to insulin in patients with type 1 diabetes. N Engl J Med 2017;377:2337–2348
13. Perkins BA, Cherney DZ, Partridge H, et al. Sodium–glucose cotransporter 2 inhibition and glycemic control in type 1 diabetes: results of an 8-week open-label proof-of-concept trial. Diabetes Care 2014;37:1480–1483
14. Pieber TR, Famulla S, Elbrachter J, et al. Empagliflozin as adjunct to insulin in patients with type 1 diabetes: a 4-week, randomized, placebo-controlled trial (EASE-1). Diabetes Obes Metab 2015;17:928–935
15. Henry RR, Thakkar P, Tong C, Polidori D, Alba M. Efficacy and safety of canagliflozin, a sodium–glucose cotransporter 2 inhibitor, as add-on to insulin in patients with type 1 diabetes. Diabetes Care 2015;38:2258–2265
16. Kuhadiya ND, Ghanim H, Mehta A, et al. Dapagliflozin as additional treatment to liraglutide and insulin in patients with type 1 diabetes. J Clin Endocrinol Metab 2016;101:3506–3515
17. Dondona P, Mathieu C, Philip M, et al. Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial. Lancet Diabetes Endocrinol 2015;3:864–876
18. Handelsman Y, Henry RR, Bloomgarden ZT, et al. American Association of Clinical Endocrinologists and American College of Endocrinology position statement on the association of SGLT-2 inhibitors and diabetic ketoacidosis. Endocr Pract 2016;22:753–762
19. Triplitt CL, Repas T, Alvarez C. Diabetes mellitus. In Pharmacotherapy: A Pathophysiological Approach. 10th ed. DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey L. Eds. New York, N.Y., McGraw-Hill, 2017, p. 1139–1181
20. American Diabetes Association. Pharmacologic approaches to glycemic treatment. Standards of Medical Care in Diabetes—2018. Diabetes Care 2018;41(Suppl. 1):S73–S85
21. Kielgaert U, Krappe T, Holst JJ, Madsbad S. Four weeks of treatment with liraglutide reduces insulin dose without loss of glycemnic control in type 1 diabetic patients with and without residual beta-cell function. Diabetes Care 2011;34:1463–1468
22. Kuhadiya ND, Malik R, Bellini NJ, et al. Liraglutide as additional treatment to insulin in obese patients with type 1 diabetes mellitus. Endocr Pract 2013;19:963–967
23. Hari Kumar KV, Shaikh A, Prusty P. Addition of exenatide or sitagliptin to insulin in new onset type 1 diabetes: a randomized, open label study. Diabetes Res Clin Pract 2013;100:e55–e58
24. Traina AN, Lull ME, Hui AC, Zahorain TM, Lyons-Patterson J. Once-weekly exenatide as adjunct treatment of type 1 diabetes mellitus in patients receiving continuous subcutaneous insulin infusion therapy. Can J Diabetes 2014;38:269–272
25. Frandsen CS, DeJgaard TF, Holst JJ, Andersen HU, Thorsteinsson B, Madsbad S. Twelve-week treatment with liraglutide as add-on to insulin in normal-weight patients with poorly controlled type 1 diabetes: a randomized, placebo-controlled, double-blind parallel study. Diabetes Care 2015;38:2250–2257
26. DeJgaard TF, Frandsen CS, Hansen TS, et al. Efficacy and safety of liraglutide for overweight adult patients with type 1 diabetes and insufficient glycaemic control (Lira-1): a randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol 2016;4:221–232
27. Kuhadiya ND, Dhindsa S, Ghanim H, et al. Addition of liraglutide to insulin in patients with type 1 diabetes and insufficient glycemic control (Lira-1): a randomized, placebo-controlled clinical trial of 12 weeks. Diabetes Care 2016;39:1027–1035
28. Mathieu C, Zinnman B, Hemmingsson JU, et al. Efficacy and safety of liraglutide added to insulin treatment in type 1 diabetes: the ADJUNCT ONE treat-to-target randomized trial. Diabetes Care 2016;39:1702–1710
29. Ahren B, Hirsch IB, Pieber TR, et al. Efficacy and safety of liraglutide added to caged insulin treatment in subjects with type 1 diabetes: the ADJUNCT TWO randomized trial. Diabetes Care 2016;39:1693–1701
30. Sanofi. FDA to review Zynquista™ (sotagliflozin) as potential treatment for type 1 diabetes. Available from www.news.sanofi.us/2018-05-22-FDA-to-review-Zynquista-TM-sotagliflozin-as-potential-treatment-for-type-1-diabetes. Accessed 18 June 2018
31. DCCT Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977–986
32. Nathan DM, Cleary PA, Backlund JY, et al. Intensive diabetes treatment and car-

169
diovascular disease in patients with type 1 diabetes. N Engl J Med 2005;353:2643–2653
33. Marso SP, Daniels GH, Brown-Brandison K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2016;375:311–322
34. Zinman B, Wanner C, Lachin JM. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015;373:2117–2128
35. Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 2017;377:644–657
36. Dubé MC, D’Amours M, Weisnagel SJ. Beyond glycaemic control: a cross-over, double-blind, 24-week intervention with liraglutide in type 1 diabetes. Diabetes Obes Metab 2018;20:178–184
37. Micromedex Solutions. Ann Arbor, Mich., Truven Health Analytics, 2018. Available from www.micromedexsolutions.com. Accessed 18 June 2018